Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481198 | 1.00 | KDM4E (0.46) | KDM4EKMT2AFABP7FABP5POLB | |
| SCHEMBL31505489 | 1.00 | KDM4E (0.46) | KDM4EKMT2AFABP7FABP5POLB | |
| SCHEMBL31398326 | 1.00 | KDM4E (0.46) | KDM4EKMT2AFABP7FABP5POLB | |
| Water SCHEMBL4955373 | 0.99 | KDM4E (0.45) | KDM4EKMT2AFABP7FABP5POLB | |
| SCHEMBL28078038 | 0.96 | KDM4E (0.44) | KDM4EKMT2AFABP7FABP5POLB | |
| SCHEMBL3206093 | 0.95 | KDM4E (0.43) | KDM4EKMT2AFABP7FABP5POLB | |
| SCHEMBL31542622 | 0.89 | CYP1A2 (0.45) | KDM4EKMT2APOLBALDH1A1CYP1A2 | |
| SCHEMBL13327274 | 0.89 | POLB (0.52) | KMT2AFABP7FABP5POLBALDH1A1 | |
| SCHEMBL22397770 | 0.89 | POLB (0.52) | KMT2AFABP7FABP5POLBALDH1A1 | |
| SCHEMBL3219970 | 0.86 | FABP5 (0.49) | KMT2AFABP7FABP5POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20230218765-A1 | SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN | UNIV MICHIGAN REGENTS (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023108031-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20200385709-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3211126-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X CHEM INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3653763-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-Chem, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3211126-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-Chem, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2002036808-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020048763-A1 | Human genome-derived single exon nucleic acid probes useful for gene expression analysis | AMERSHAM PLC (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020048800-A1 | Myosin-like gene expressed in human heart and muscle | GE HEALTHCARE LIMITED (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002026818-A2 | HUMAN NEDD-1 | AEOMICA, INT. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024750-A2 | HUMAN KIDNEY TUMOR OVEREXPRESSED MEMBRANE PROTEIN 1 | AEOMICA, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001092524-A2 | MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE | AEOMICA, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385709-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PCNA, DNA2, POLM | KDM4E 3069/4885KMT2A 2085/4885FABP7 2512/4885 |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | PCNA, DNA2, POLM | KDM4E 4406/4885KMT2A 3602/4885FABP7 1854/4885 |
| US-20230218765-A1 | SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN | PTPN1, PTPRS, PPM1D | KDM4E 251/4885KMT2A 675/4885FABP7 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.